SUNNYVALE, Calif., April 22, 2016 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) announced today that the Accuray
Exchange in Radiation Oncology (AERO™) Users' Meeting was held
April 10 – 11, 2016 at the Palace
Hotel in San Francisco,
California. The two day summit, coordinated in partnership
with teams from several University of
California campuses, brought together radiation oncologists,
physicists, therapists and administrators from around the world to
discuss best practices and the future of radiation oncology.
Founded in 2011, AERO was created for CyberKnife® System
and TomoTherapy® System users dedicated to advancing
patient care through worldwide clinical and technical
collaboration.
Further information on Accuray, the CyberKnife and TomoTherapy
Systems is available at www.accuray.com.
"It was stated repeatedly that this Users' Meeting was to be
considered 'our' meeting – our opportunity as clinicians who have
invested in the CyberKnife and/or TomoTherapy technology to come
together to learn more to help our patients. But it was much more.
It was a trifecta gathering to, (1) find out what is on the
industry roadmap for the future, (2) understand results of new
clinical strategies and trials that push the barriers of technology
at clinics around the world, and (3) meet and associate with new
colleagues to form collaborations that will continue to improve
patients' care, outcomes, and quality of life," said Stanley H. Benedict, Ph.D., professor & vice
chair of Clinical Physics, Department of Radiation Oncology,
University of California at Davis
Comprehensive Cancer Center and a speaker at the meeting.
More than two dozen specialized breakout sessions provided
meeting participants with the opportunity to engage in peer-to-peer
conversation related to delivering improved patient outcomes with
fewer side effects and enhanced quality of life, at a reduced cost.
An "Originators and Innovators" session featured presentations on
the history behind the CyberKnife and TomoTherapy Systems, and
innovative approaches clinicians are taking these technologies
today to elevate radiation oncology to the next level. Additional
meeting highlights included:
- A special session focused on "A New Paradigm in Expediting
Quality Care in Radiation Therapy"
- A discussion about "Healthcare Economics: Market Trends and
Transformation"
- A keynote address on "The Future of Radiation Oncology"
- Sessions specially designed for Administrators
"The CyberKnife and TomoTherapy users in attendance represent a
distinguished group of practitioners who are advancing the use of
radiation therapy across all cancer types," said Joshua H. Levine, president and chief executive
officer of Accuray. "The information sharing that happens at these
meetings is focused on an important goal – improving patient
outcomes. The insights we gain through interacting with clinicians
at this meeting will influence our product roadmap and drive
technical innovations toward that goal."
The AERO community mission is to provide a global forum for the
clinical exchange of information between clinicians and physicists
for the purpose of setting a new standard in patient care and
safety across treatments in the fields of SRS/SBRT, IMRT and
conventional radiation therapy. Membership to AERO is free and open
to all users of the CyberKnife® and
TomoTherapy® Systems. Accuray is pleased to sponsor the
2016 Accuray pre-ESTRO Planning Workshop for all AERO™ members, to
be held at the Hotel AlegroItalia Golden Palace in Turin, Italy on Thursday, April 28, 2016, from 12:00pm to 5:45pm. To learn more, visit
www.accurayexchange.com.
About the CyberKnife M6™ Series and TomoTherapy H™ Series
Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series
treatment solutions cover the entire spectrum of radiation therapy
needs. The CyberKnife M6 Series enables precise, high-quality,
high-dose distributions to be confidently delivered to the patient
with extreme accuracy over a minimum number of treatments, reducing
side effects and preserving patients' quality of life. The
CyberKnife System is the only robotic full-body radiosurgery system
available today. The TomoTherapy H Series System efficiently
enables physicians to customize treatment plans for the entire
range of radiation therapy patients and disease types. Its
innovative design enables treatment plans to be delivered with
integrated, daily CT image guidance, enhancing accuracy and
delivering highly precise, intensity-modulated radiation for
optimal sparing of healthy tissue and critical structures.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes and Accuray's leadership
position in radiation oncology innovation and technologies, as well
as its future product offerings. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from expectations, including but not limited
to the risks detailed from time to time under the heading "Risk
Factors" in the company's report on Form 10-K, filed on
August 28, 2015, the company's
reports on Form 10-Q, filed on November 5,
2015 and February 1, 2016, and
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Danielle Sullivan
MSLGROUP
+1 (781) 684-0770
Danielle.Sullivan@MSLGROUP.com
Logo - http://photos.prnewswire.com/prnh/20160108/320376LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/accuray-hosts-regional-aero-users-meeting-300255897.html
SOURCE Accuray Incorporated